Please ensure Javascript is enabled for purposes of website accessibility

Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdle

By Cory Renauer – Updated Jun 22, 2020 at 11:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Early safety data for the potential one-shot cure for the lethal muscle wasting disorder looks encouraging.

A once-and-done gene therapy candidate that could halt the progression of a lethal muscle-wasting disorder took an important step on the path toward approval Monday. Results of a clinical trial published by the Journal of the American Medical Association strongly suggest that Sarepta Therapeutics' (SRPT -0.03%) SRP-9001 will become a safe treatment option for boys born with Duchenne muscular dystrophy (DMD). 

Positive clinical trial results 

Back in 2017, Sarepta began a safety study with four boys born with DMD, a rare inherited disorder caused by a mutated dystrophin gene. Without functional dystrophin to protect their muscles, DMD patients inflict muscle damage on themselves with every movement, breath, and heartbeat. SRP-9001 is a non-replicating adenovirus that delivers a portion of the working dystrophin gene to muscle cells. So far, none of the four participants have reported adverse events serious enough to require hospitalization.

Scientist reading a report.

Image source: Getty Images.

About SRP-9001's efficacy

That lack of serious adverse events means the safety study was a success, and it looks like future outcome assessments will hit the mark as well. Investigators took muscle tissue samples 12 weeks after patients received SRP-9001 and found proof of micro-dystrophin generation in 82% of fibers sampled.

Creatine kinase (CK) leaks from damaged muscles into the bloodstream, but one year after treatment with SRP-9001, patients' CK levels were much lower than expected, with the exception of one who was probably a little too active just ahead of his 52-week assessment. Since the average age of these patients was less than 5 years old, getting them to sit still is much easier said than done.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$109.91 (-0.03%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.